Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Judge sets $60K bond for Florida congresswoman accused of stealing $5M in COVID-19 funds - 2They grew up with 'almond moms.' Now, they dread going home for the holidays.
- 34 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- 4How Would You Like to Deal with Your Funds?
- 5AfD faction in western Germany ousts councilman for firebrand speech
- Kendall Jenner addresses long-standing rumor about her sexuality
- 'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
- Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
- I work with companies to confront addiction in the workplace. The hidden crisis is costing corporate America millions.
- Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- The Golden Globes gift bag has nearly $1 million worth of swag for some winners and presenters. What's in it?
- How Mars' ancient lakes grew shields of ice to stay warm as the Red Planet froze
- Support Your Body: A Manual for Smart dieting and Sustenance
- The Electric Bicycle Americans Can Confide in 2024
